Home › NCT07127354

The Impact of GLP Medication on Colonoscopy Bowel Preparation Quality

The Impact of GLP-1 Agonist and GIP Agonist on Bowel Preparation Quality: A Randomized Controlled Trial

Who can join

Ages 18 and older · All sexes · Healthy volunteers welcome

Inclusion Criteria:

* Adult patient (Age 18 years or older)
* Patient scheduled for outpatient screening, surveillance, or diagnostic colonoscopy
* Using a GLP-1 or GIP agonist at a stable dose for at least one month

Exclusion Criteria:

* Unable to provide informed consent, e.g., dementia
* Patient refuses the USMSTF recommended bowel cleansing regimen for patients with diabetes or obesity (split-dose 4 liters polyethylene glycol + 15 mg bisacodyl the afternoon before; low residue diet 3 days before colonoscopy; clear liquid diet the day before colonoscopy)
* Risk factors for inadequate bowel preparation besides diabetes and obesity with a likelihood ratio of 1.6 or greater:

  1. Cirrhosis
  2. Parkinson's disease
  3. Dementia
  4. Tricyclic antidepressant use
  5. Opioid use
  6. Gastroparesis\* or suspected gastric outlet obstruction on pre-procedure imaging (\*defined based on a documented 4-hour solid phase gastric emptying study or prior history of retained gastric contents during upper endoscopy)
  7. Previous colorectal surgery
  8. Prior history of inadequate bowel preparation

About the study

The goal of this clinical trial is to learn how GLP-1 and GIP agonists effect bowel preparation in patients scheduled for colonoscopies. The main questions it aims to answer are:

* Does GLP-1 and GIP agonist increase the rate of inadequate bowel preparation? * Does the quality of bowel preparation differ in patients who hold vs. those who continue a single dose of their GLP-1 or GIP agonist medication? * Are there any differences in the rates of complications gastric aspiration in patients who hold vs. continue a single dose of their GLP-1 or GIP agonist medication?

What is being tested

• Continue GLP/GIP (drug)

Sponsor: The Cleveland Clinic · Participants: 132 · Started: Aug 1, 2025

Contact the study team

Official record on ClinicalTrials.gov — NCT07127354

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.